

CHAIRMAN'S BRIEF ACVSB MEETING ON 24 APRIL 1990

INTRODUCTION

There is lunch arranged in the canteen at 13.00 Meeting can be reconvened afterwards if necessary.

APOLOGIES

So far apologies have been received from:-

- Dr Minor (NIBSC) - Dr Garrett attending instead
- Dr Jacobs (Welsh Office)
- Dr Purves (MCA) - Mr Sloggem attending instead

An update will be provided on Tuesday morning.

MINUTES OF THE LAST MEETING

These have been circulated and no corrections received so far. Comments can be invited at the meeting before minutes are approved as a correct record.

MATTERS ARISING

You may wish to confirm that the Secretariat have not received any comments on paper ACVSB 5/2 tabled by Dr Minor at the last meeting.

EC DIRECTIVE ON BLOOD PRODUCTS

No substantial change since last meeting - Mr Sloggem will therefore give an oral report.

HIV1 AND 2-TESTING

The UK Health Ministers approved the introduction of combined HIV1 and 2 testing after the last meeting. Dr Gunson should be asked to report on date of implementation (will be 1 June) and on which test(s) are to be used. At the time of the last meeting the evaluation of the Wellcome test had not been completed and unlike the other tests it had a higher price than the company's HIV1 only test. We understand that the price differential has been reduced and the test is likely to be acceptable to RTCs because of its other advantages.

*John +
Gordon 11* } May wish to mention that the FDA have approved HIV2 tests but refused to endorse routine testing of all blood donations.

HTLV1 TESTING

At the last meeting it was reported that a protocol and request for funding for a UKBTS Pilot Study would be coming to the Department shortly. Not yet received and Dr Gunson should be asked where matters stand.

HEPATITIS C

You may wish to mention paper ACVSB 6/1 (published items on efficacy of new tests and pressures for testing) which was circulated to members for information. Of the four papers listed on the agenda only ACVSB 6/2 (Ortho symposium) has been circulated before the meeting and the others will be tabled. Therefore it may be sensible to have all the papers introduced before inviting general discussion. The papers will be introduced as follows:

ACVSB 6/2 (Ortho symposium) → Dr Rejman ←

to come ACVSB 6/3 (Abbott symposium) - Dr Mitchell

to come ACVSB 6/4 (FDA situation) - Mr Sloggem

ACVSB 6/5 (Conference Report) - Prof Zuckerman, but others
ACVSB 6/6 (?)
(possibly Dr Mortimer) may contribute reports as well. In any event Dr Mortimer should be asked his views as we understand he attended.

ACVSB 6/1

In addition to these papers ACVSB 6/6 will have been tabled. This gives our Economic Advisers preliminary views on the cost/benefits of testing and outlines the factors still to be considered in detail. Mr Canavan will introduce this paper.

GRO-C

ANY OTHER BUSINESS

None from our side.

DATE OF NEXT MEETING

This will depend on the outcome of the discussion on Hepatitis C testing. A date in July could be pencilled in for any urgent business but otherwise the next routine meeting could be held second half September or early October.